Cargando…
FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications
This paper describes a new FDA’s pharmaceutical quality assessment system: Knowledge-aided Assessment & Structured Application (KASA). The KASA system is designed to: 1) capture and manage knowledge during the lifecycle of a drug product; 2) establish rules and algorithms for risk assessment, co...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733282/ https://www.ncbi.nlm.nih.gov/pubmed/31517275 http://dx.doi.org/10.1016/j.ijpx.2019.100010 |
_version_ | 1783449951547686912 |
---|---|
author | Yu, Lawrence X. Raw, Andre Wu, Larisa Capacci-Daniel, Christina Zhang, Ying Rosencrance, Susan |
author_facet | Yu, Lawrence X. Raw, Andre Wu, Larisa Capacci-Daniel, Christina Zhang, Ying Rosencrance, Susan |
author_sort | Yu, Lawrence X. |
collection | PubMed |
description | This paper describes a new FDA’s pharmaceutical quality assessment system: Knowledge-aided Assessment & Structured Application (KASA). The KASA system is designed to: 1) capture and manage knowledge during the lifecycle of a drug product; 2) establish rules and algorithms for risk assessment, control, and communication; 3) perform computer-aided analyses of applications to compare regulatory standards and quality risks across applications and facilities; and 4) provide a structured assessment that minimizes text-based narratives and summarization of provided information. When fully developed and implemented, KASA will enrich the effectiveness, efficiency, and consistency of regulatory quality oversight through lifecycle management of products and facilities, and information sharing in a standardized and structured format. Ultimately, KASA will advance FDA’s focus on pharmaceutical quality, the foundation for ensuring the safety and efficacy of drugs. |
format | Online Article Text |
id | pubmed-6733282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-67332822019-09-12 FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications Yu, Lawrence X. Raw, Andre Wu, Larisa Capacci-Daniel, Christina Zhang, Ying Rosencrance, Susan Int J Pharm X Article This paper describes a new FDA’s pharmaceutical quality assessment system: Knowledge-aided Assessment & Structured Application (KASA). The KASA system is designed to: 1) capture and manage knowledge during the lifecycle of a drug product; 2) establish rules and algorithms for risk assessment, control, and communication; 3) perform computer-aided analyses of applications to compare regulatory standards and quality risks across applications and facilities; and 4) provide a structured assessment that minimizes text-based narratives and summarization of provided information. When fully developed and implemented, KASA will enrich the effectiveness, efficiency, and consistency of regulatory quality oversight through lifecycle management of products and facilities, and information sharing in a standardized and structured format. Ultimately, KASA will advance FDA’s focus on pharmaceutical quality, the foundation for ensuring the safety and efficacy of drugs. Elsevier 2019-03-17 /pmc/articles/PMC6733282/ /pubmed/31517275 http://dx.doi.org/10.1016/j.ijpx.2019.100010 Text en Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Yu, Lawrence X. Raw, Andre Wu, Larisa Capacci-Daniel, Christina Zhang, Ying Rosencrance, Susan FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications |
title | FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications |
title_full | FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications |
title_fullStr | FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications |
title_full_unstemmed | FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications |
title_short | FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications |
title_sort | fda’s new pharmaceutical quality initiative: knowledge-aided assessment & structured applications |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733282/ https://www.ncbi.nlm.nih.gov/pubmed/31517275 http://dx.doi.org/10.1016/j.ijpx.2019.100010 |
work_keys_str_mv | AT yulawrencex fdasnewpharmaceuticalqualityinitiativeknowledgeaidedassessmentstructuredapplications AT rawandre fdasnewpharmaceuticalqualityinitiativeknowledgeaidedassessmentstructuredapplications AT wularisa fdasnewpharmaceuticalqualityinitiativeknowledgeaidedassessmentstructuredapplications AT capaccidanielchristina fdasnewpharmaceuticalqualityinitiativeknowledgeaidedassessmentstructuredapplications AT zhangying fdasnewpharmaceuticalqualityinitiativeknowledgeaidedassessmentstructuredapplications AT rosencrancesusan fdasnewpharmaceuticalqualityinitiativeknowledgeaidedassessmentstructuredapplications |